Business

Know the Business — Supreme PLC

Bottom line. Supreme is a UK vertically-integrated branded FMCG manufacturer-distributor whose moat is the relationship with UK retail buyers — vape, drinks, sports nutrition, batteries and lighting all flow through one Manchester warehouse to the same 3,000+ trade accounts. Earnings are concentrated in vaping (~56% of revenue, ~36% gross margin), and the market prices the whole company at a regulated-tobacco-adjacent multiple (5x EV/EBITDA, 8x P/E) while management spends £50m+ to halve that vape mix. The market is paying for the vape regulatory mix and giving the platform rotation for free; whether that read is right depends on what vape gross margin does after the 1 October 2026 duty.

1. How This Business Actually Works

Supreme makes money by getting branded or licensed products onto a UK retailer's planogram, shipping them from one Trafford Park hub, and earning manufacturer-plus-distributor margin on each pallet. Three things drive incremental profit: (1) which category the next pallet goes into — vape contributes >2x the gross-margin density of electricals, (2) whether Supreme owns or just distributes the brand on it — own-brand and in-house manufactured SKUs earn 1.5-2x the gross margin of factored OEM, and (3) how fast the inventory turns — at 70 inventory days and 61-day cash-conversion-cycle, working capital, not capex, is the binding constraint.

The vertical-integration premium. A pure UK FMCG distributor (Bunzl, Kitwave) earns single-digit gross margin. A pure manufacturer (Premier Foods) earns ~38% on a much heavier asset base. Supreme runs a 32% blended gross margin on £30m of net PP&E because it manufactures in-house in vaping (e-liquid, devices), sports nutrition (powders, gels), and now drinks (Clearly Drinks, Typhoo) — and licenses globally-recognised brands (Energizer, JCB) the retailer can't source elsewhere at scale. The same Manchester warehouse, sales team and ABL facility carry all of it.

Working capital is the choke point, not capex. Capex ran £3-5m on a £200m revenue base for years. The real capital signature is the £36m of inventory and £42m of receivables on the FY25 balance sheet, financed by a £40m HSBC asset-based lending facility (£34m undrawn at H1 FY26). Working capital widened by £11m in H1 FY26 — partly the seasonal pre-Christmas inventory build, partly a deliberate switch from air-freight to sea-freight on vape lines (lengthening stock-in-transit by weeks for the sake of long-term margin). When Supreme grows organically, cash unwinds; when it shifts mix or acquires, working capital absorbs cash before the synergies show.

Bargaining power runs against Supreme on the customer side and with it on the supplier side. One UK retailer (almost certainly B&M, Home Bargains or a comparable variety discounter) accounted for £21m of H1 FY26 revenue (16% of group); two customers were >10% in H1 FY25. That is the price of being a value-led FMCG supplier into a concentrated UK retail market. The defenses are owning the brand the consumer asks for (Typhoo, SCI-MX, SlimFast), holding a long-running licence the retailer cannot replicate (Energizer to 2030, JCB renewed), and being the only UK supplier with the vertical footprint to ship UK-made stock at speed.

2. The Playing Field

Latest reported FY for each name; market caps as of late April / early May 2026. SUP reflects FY25 (Mar-2025) and 162.5p close.

What the peer set reveals. Supreme's margin profile sits between Premier Foods (mature multi-cat branded) and the soft-drinks/wellness pure-plays — but its multiple sits below all of them and only slightly above HFG, a low-margin food packer. The market is paying for the regulated-vape mix and the working-capital fragility, not for the platform optionality. The two structural takeaways:

• No peer competes across all three of Supreme's categories. NICL is the soft-drinks comparable, APN the sports-nutrition comparable, IMB the vape comparable, PFD the closest multi-cat branded food template. None has Supreme's exact mix, which is exactly why no single multiple fits.
• "Good" in this peer set means high margin density on low capex. Applied Nutrition (27% EBITDA margin, 0.9% capex/rev, 34% ROIC) is the best-in-class economic model — and trades at 10.5x EV/EBITDA on 24% growth. Supreme's underlying ROIC (30%) and capex/rev (1.4%) are already in that neighbourhood; the mix is what separates them. APN does not yet have to bridge a regulated-revenue runoff; Supreme does.

The honest read: Supreme is an APN-quality return engine bolted onto an IMB-style regulated vape revenue stream, distributed through a PFD-style multi-category platform. The market prices it as the IMB part — the rest is conditional optionality on the rotation working.

3. Is This Business Cyclical?

Supreme is not economically cyclical — it is regulatory cyclical. GDP-recession beta is low because the value end of UK FMCG benefits from down-trading; that is observable in 8 years of EBITDA, which has compounded ~22% even through 2020-22. The cycle that matters is the regulated-vape pulse, and it is on a published timetable.

The disposable ban was the first regulatory shock; it is essentially absorbed. The £2.20-per-10ml vape duty (1 Oct 2026) is the second and the harder one — it adds 44p of duty to a 2ml replacement pod and £2.20 to a 10ml e-liquid bottle. Whether this compresses Supreme's margin or passes through to retail price depends on the elasticity of the consumer and the willingness of B&M / Home Bargains to take the price increase. The pod-format gross margin compression in H1 FY26 (33% → 31%) is the early read; if it holds at that level post-duty, the bear case is contained. If it slides toward 25%, the rotation thesis is in trouble.

4. The Metrics That Actually Matter

Latest values: vape mix and gross margin from H1 FY26 (Vaping £76.9m of £132.6m group, 31% GM); D&W GM, CCC, ROIC, FCF conversion from FY25; net debt / EBITDA from H1 FY26 adjusted (£4.1m / £37m run-rate).

The standard FMCG ratios (operating margin, asset turnover, dividend yield) are not the right lens here. The question this business resolves to is whether the mix rotation from regulated vape to branded drinks/wellness happens at a rate that preserves group EBITDA. That is what these eight numbers track. Vape gross margin and Drinks & Wellness gross margin convergence are the two that move the stock; net debt / EBITDA tells you whether management can keep buying assets without diluting; CCC and FCF conversion tell you whether the unit growth is real cash or accounting bulk.

5. What Is This Business Worth?

The right valuation lens is one branded-FMCG platform with a segment-mix overlay — not strict sum-of-the-parts, because the segments are run from one warehouse, one ABL facility, and one sales force, and you cannot sell vaping without selling the platform. But the segments do deserve different multiples, and the consolidated EV/EBITDA hides that.

An indicative segment lens (illustrative only — Supreme does not disclose segment EBITDA, so the split below allocates group Adj EBITDA by gross-profit share, which understates vape and overstates drinks):

The cleaner way to underwrite is to ask three questions. First, is the underlying ROIC durable? Five-year ROIC has held above 27% through a doubling of revenue and three substantial acquisitions; that is best-in-peer-set. Second, is the FCF real? FY25 FCF/EBITDA was 53% on growing capex; H1 FY26 operating cash dropped to £3.8m mostly on freight-shift working capital — needs to unwind. Third, what does management do with cash? They are reinvesting at deal multiples that look inside 1.5x revenue (Clearly Drinks £15m on £30m+ revenue, SlimFast £20m on ~£20m run-rate revenue, 1001 £1.65m + earnouts on a heritage carpet brand). If those acquisition multiples convert to group ROIC over 24-36 months, the platform value is in the £270m+ range — if.

6. What I'd Tell a Young Analyst

Don't anchor on "AIM-listed UK FMCG." Anchor on segment economics. Supreme blends a 36%-GM regulated category, a 29%-GM growing branded category and a 20%-GM declining one. The consolidated 32% GM is meaningless without the mix; track each one separately and the group story comes into focus.

The two numbers that move the stock are vape gross margin and the disposable runoff. Disposable revenue is essentially zero now — that fight is done, and the stock has not rerated for it. Vape GM compressed 200bps in H1 FY26 in the pod transition; the question is whether that is a one-time reset or the start of a slide. Watch the H2 FY26 print and the first post-duty disclosure (FY27 H1).

Working-capital days are the early-warning system. A platform that compounds revenue 20% over five years on a £40m ABL facility either converts well or it doesn't. CCC at 61 days in FY25 says it does. If the H1 FY26 working-capital outflow does not unwind by year-end, you have a quality problem the headline EBITDA will hide.

The M&A engine is the actual investment thesis. Supreme is a UK consolidation play sized like a small-cap vape stock. Five deals in 18 months at sub-1.5x revenue, financed off-balance-sheet through an ABL that has £34m undrawn. If management cannot keep that cadence, 5x EV/EBITDA is fair; if they can, the implied multiple is 7-8x.

What would change the thesis. Equity raise to fund the next deal (dilutes the per-share story); a regulatory restriction on vape flavours under the new bill (compresses the engine that funds the rotation); ABL covenant breach (forces working-capital discipline at the worst time). None is a base case; all are observable in single RNS prints. Read every RNS announcement; this is not a stock you valuation-screen and forget.